---
title: "VICO: Buloxibutid shows strong efficacy and safety for IPF, advancing in a pivotal global Phase 2b trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296869802.md"
description: "Focused on developing buloxibutid, an oral AT2 receptor agonist, for IPF, the company has shown promising efficacy and safety in clinical trials, with a robust mechanism targeting tissue repair and fibrosis. Positioned for global leadership, it is well-funded, has a major partnership in Japan, and is advancing through a pivotal Phase 2b trial.Original document: Vicore Pharma Holding AB [VICO] Slides Release — Aug. 25 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-25T06:44:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296869802.md)
  - [en](https://longbridge.com/en/news/296869802.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296869802.md)
generator: "portal-rs"
---

# VICO: Buloxibutid shows strong efficacy and safety for IPF, advancing in a pivotal global Phase 2b trial

Focused on developing buloxibutid, an oral AT2 receptor agonist, for IPF, the company has shown promising efficacy and safety in clinical trials, with a robust mechanism targeting tissue repair and fibrosis. Positioned for global leadership, it is well-funded, has a major partnership in Japan, and is advancing through a pivotal Phase 2b trial.

Original document: Vicore Pharma Holding AB \[VICO\] Slides Release — Aug. 25 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [VCRE.US](https://longbridge.com/en/quote/VCRE.US.md)

## Related News & Research

- [Microsoft employees reveal how much cash they're burning on AI](https://longbridge.com/en/news/296828490.md)
- [WSHP: First half 2026 results released, highlighting platform growth and ongoing user ownership initiatives](https://longbridge.com/en/news/296829514.md)
- [ETFs RDVY, BKLC, and LSGR Get Bullish Calls from AI for Growth Potential](https://longbridge.com/en/news/296821798.md)
- [Reports Say Anthropic Sees Potential Revenue Exceeding USD30 Trillion, Surpassing Space Exploration Technologies Corp.](https://longbridge.com/en/news/296983142.md)
- [Sao Paulo’s Sabesp launches BRL 156.64 million debenture offering](https://longbridge.com/en/news/297031912.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**